---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-048823"
form_type: "8-K"
ticker: "STSS"
cik: "0001737995"
company_name: "Sharps Technology Inc."
filed_at: "2024-12-05T23:59:59+00:00"
generated_at: "2026-05-29T07:20:28.559293+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sharps Technology signs $50M+ SoloGard syringe deal; sets $5M 2025 revenue target

## Summary
- Entered $50M+ 5-year supply agreement for 500M SoloGard 10mL syringes with U.S. pharma company; deliveries begin Q1 2025.
- Signed sales agreement with European medical supply company for SecureGard 1mL/3mL inventory; first revenue in early December 2024.
- Revenue guidance: ~$400K Dec 2024, >$5M in 2025, $15M in 2026, $20M in 2027 from Hungary facility.
- Regained compliance with NASDAQ listing rules as of November 13, 2024.
- Hungary expansion targets SecureGard capacity >100M units and SoloGard >125M units annually.

## SEC filing metadata
- accession: 0001493152-24-048823
- form_type: 8-K
- ticker: STSS
- cik: 0001737995
- company_name: Sharps Technology Inc.
- filed_at: 2024-12-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737995/000149315224048823/0001493152-24-048823-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737995/000149315224048823/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-048823
- JSON: https://secwatch.observer/filing/0001493152-24-048823.json
- Plain text: https://secwatch.observer/filing/0001493152-24-048823.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.